Tag: cytokinetics
January 7, 2020
Cytokinetics Starts Phase 2 Clinical Trial for Cardiomyopathy Treatment
The company said its myosin inhibitor will be evaluated to optimize its dosing schedule to a therapeutic window for patients... January 6, 2020
Cytokinetics Announces Start of Phase 2 Clinical Trial of CK-3773274
Cytokinetics announced that REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM) has opened to enrollment. August 27, 2019
Cytokinetics and Cure SMA Renew Partnership
Cure SMA and Cytokinetics (NASDAQ:CYTK) have renewed their partnership to increase and raise awareness for spinal muscular atrophy (SMA). As... July 23, 2019
Cytokinetics Granted European Orphan Designation for Reldesemtiv to Treat Spinal Musclar Atrophy
Cytokinetics (NASDAQ:CYTK) has announced that the European Medicines Agency (EMA) has granted the company orphan medicinal product designation to reldesemtiv... February 20, 2019
Cytokinetics Announces Initiation of Phase 1 Clinical Study of AMG 594, a Cardiac Troponin Activator
Cytokinetics (NASDAQ:CYTK) has announced the first subject has been dosed in a Phase 1 randomized, double-blind, placebo-controlled and multiple ascending... December 5, 2018
Cytokinetics Announces Initiation of Phase 1 Clinical Trial of CK-3773274
Cytokinetics (Nasdaq:CYTK) announced the first subject has been dosed in a Phase 1 double-blind, randomized, placebo-controlled, multi-part, single and multiple... October 5, 2018